Back to Stocks

DCTH

DELCATH SYSTEMS, INC.
7 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Delcath Systems is successfully transitioning from a clinical-stage entity to a commercial growth company. The latest quarterly results highlight a significant 26% year-over-year increase in total revenue, reaching $25 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, Delcath's underlying profitability is deteriorating. The company reported an operating loss of $1.6 million for the quarter, as total operating expenses surged 41% year-over-year to $22.9 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every DCTH filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic biotech trade-off: impressive commercial acceleration versus widening operational losses. Delcath has proven that HEPZATO has a viable market and strong pricing power, but the cost of scaling that business and pursuing new indications is mounting. The shift from a single-indication company to a multi-indication oncology platform is the primary value driver, yet it requires a sustained increase in R&D spending that is currently weighing on the bottom line. The overall impact of the filing is a mixture of short-term financial pressure and long-term strategic expansion. While the net loss and customer concentration are cautionary, the sheer scale of the cash position relative to the current burn rate provides a significant safety margin. The market's reaction will likely hinge on whether the revenue growth can accelerate fast enough to reach a break-even point before the cash reserves are depleted by the upcoming Phase 2 trial readouts.

Selected Quarter

Core Takeaway

Delcath is successfully commercializing HEPZATO but is spending aggressively to expand its TAM, leading to a net loss despite strong gross margins.

Investor Lens

The trade-off is between current bottom-line losses and the potential for a multi-billion dollar TAM expansion into colorectal and breast cancers.

Watch Next

Patient enrollment progress and initial safety data for the Phase 2 mCRC and mBC trials.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%
bearishMay 7

Company reported a net loss of $1.07 million due to surging R&D and SG&A expenses.

earnings miss
60%
bullishMay 7

Maintained a high gross margin of 85.1% on $25 million in revenue.

margin expansion
90%
bullishMay 7

Repurchased $9 million of common stock as part of a $25 million authorization.

buyback
50%
bearishMay 7

Significant potential dilution from 8.6 million outstanding options and 1.3 million warrants.

dilution risk
70%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a classic biotech trade-off: impressive commercial acceleration versus widening operational losses. Delcath has proven that HEPZATO has a viable market and strong pricing power, but the cost of scaling that business and pursuing new indications is mounting. The shift from a single-indication company to a multi-indication oncology platform is the primary value driver, yet it requires a sustained increase in R&D spending that is currently weighing on the bottom line. The overall impact of the filing is a mixture of short-term financial pressure and long-term strategic expansion. While the net loss and customer concentration are cautionary, the sheer scale of the cash position relative to the current burn rate provides a significant safety margin. The market's reaction will likely hinge on whether the revenue growth can accelerate fast enough to reach a break-even point before the cash reserves are depleted by the upcoming Phase 2 trial readouts.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.